As of March 31, 2008, Pharmasset had approximately $63.0 million of cash and cash equivalents and approximately $1.2 million of short-term investments.
"R7128 for the treatment of hepatitis C virus (HCV) continues to
demonstrate best-in-class potential based on its safety, efficacy and high
barrier to resistance as demonstrated in 4-week Phase 1 clinical trials,"
stated Schaefer Price, Pharmasset's Chief Executive Officer. "We look
forward to continuing the advancement and broadening the scope of this
program by exploring additional Phase 1 cohorts, including an R7128 1000mg
dose in patients with HCV genotype 1 and an R7128 1500mg dose in patients
with HCV genotypes 2 and 3 who have not responded to prior therapy. We and
Roche are currently focused on planning a global 12-week Phase 2b
combination study of R7128 with Pegasys plus Copegus."
Highlights of the Quarter Ended March 31, 2008
-- Announced preliminary safety and efficacy results of two cohorts (500mg
and 1500mg) in a 4-week combination study of R7128 with Pegasys plus
Copegus for the treatment of HCV.
-- Appointed Herbert J. Conrad as a member of our Board of Directors and
the Nominating and Corporate Governance Committee.
-- Advanced a new series of proprietary nucleoside analogs that have
demonstrated potent anti-HCV activity.
-- Initiating dosing and announcing preliminary results of Cohorts 3 and 4
in a 4-week combination study of R7128 with Pegasys plus Copegus for
the treatment of HCV in the third calendar quarter of 2008.
-- Completing HBV patient enrollment for clevudine Phase 3 registration
studies in the second calendar half of 2008.
-- Initiating trial activities for a global 12-week Phase 2b combination
study of R7128 with Pegasys plus Copegus in the fourth calendar quarter
|SOURCE Pharmasset, Inc.|
Copyright©2008 PR Newswire.
All rights reserved